AM Squared Ltd Buys New Shares in DexCom, Inc. (NASDAQ:DXCM)

AM Squared Ltd bought a new stake in DexCom, Inc. (NASDAQ:DXCM) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 6,300 shares of the medical device company’s stock, valued at approximately $422,000. DexCom accounts for about 0.9% of AM Squared Ltd’s investment portfolio, making the stock its 10th biggest holding.

Other institutional investors have also recently bought and sold shares of the company. Crewe Advisors LLC purchased a new stake in DexCom in the first quarter valued at approximately $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in DexCom during the second quarter valued at approximately $25,000. Sachetta LLC lifted its position in DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after buying an additional 171 shares in the last quarter. DT Investment Partners LLC lifted its position in DexCom by 492.2% during the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after buying an additional 315 shares in the last quarter. Finally, Riverview Trust Co lifted its position in DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on DXCM shares. Sanford C. Bernstein lifted their price target on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Baird R W cut shares of DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Leerink Partners reduced their target price on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Finally, Stifel Nicolaus boosted their target price on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, August 23rd. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, DexCom presently has an average rating of “Moderate Buy” and an average target price of $104.59.

DexCom Trading Up 1.6 %

DXCM opened at $75.88 on Friday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The firm’s fifty day moving average price is $70.03 and its 200 day moving average price is $91.42. The stock has a market capitalization of $29.64 billion, a PE ratio of 45.44, a P/E/G ratio of 2.33 and a beta of 1.17.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This represents a 0.28 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is owned by insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.